The Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) have unveiled a new collaborative framework aimed at speeding up patient access to innovative medicines across England. The initiative introduces an aligned pathway and an enhanced advice service designed to simplify regulatory processes and provide greater certainty for pharmaceutical companies.
Set to launch on 1 April, the aligned pathway will synchronize the decision-making timelines of both organizations. Traditionally, MHRA licensing approvals and NICE’s assessments of a drug’s clinical and cost effectiveness occurred sequentially, often causing delays. Under the new system, both processes will run in parallel, enabling decisions on licensing and value to be made simultaneously. This reform is expected to reduce the time it takes for medicines to reach patients by up to six months.
The initiative builds on commitments outlined in the government’s 10 Year Health Plan for England and its Life Sciences Sector Plan, which emphasize closer collaboration between regulatory and health technology assessment bodies. By aligning their processes, MHRA and NICE aim to remove inefficiencies and accelerate access to safe and effective treatments within the National Health Service (NHS).
Alongside the pathway, the agencies have launched an improved Integrated Scientific Advice service. This service introduces a single-entry point for companies seeking regulatory and reimbursement guidance, offering a streamlined process that includes one meeting and a unified fee structure. While advice from each body will remain independent, it will be coordinated on key areas where misalignment can occur, such as clinical trial endpoints and patient population selection.
The new advisory framework is expected to help pharmaceutical developers design stronger clinical programs from the outset, minimizing the risk of delays later in the approval process. By clarifying regulatory expectations and evidence requirements early, companies can better align their development strategies with both licensing and reimbursement criteria.
The announcement was made at the NICE Conference by NICE Chief Executive Jonathan Benger and MHRA Chief Executive Lawrence Tallon. Both leaders emphasized that the collaboration marks a significant step toward a more efficient healthcare system.
UK Health Innovation and Safety Minister Zubir Ahmed highlighted the patient impact, noting that reducing regulatory barriers will enable faster access to cutting-edge treatments and support recovery outcomes. He also pointed to the broader economic benefits, stating that clearer and quicker decisions would enhance the UK’s attractiveness as a global hub for life sciences investment.
Since October 2025, 27 pharmaceutical companies have signed up as early adopters of the aligned pathway, with the first medicines already progressing through the system. Initial guidance from the program is expected to be issued in June 2026, signaling a new era of coordinated, efficient drug approval in the UK.